Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin®) in CD1 mice following intravenous and intraperitoneal injection

Investigational New Drugs

Volumn 24, Issue 4, 2006, Pages 281-289

  Boswell, G W ^a   Miles, D R ^a   Thiemann, P A ^a   Mesfin, M ^a  

^a PHARMACYCLICS INC   (United States)

Author keywords

Bioavailability; Intraperitoneal dose; Intravenous dose; Motexafin Gadolinium; Mouse pharmacokinetics; Population pharmacokinetics

Indexed keywords

GADOLINIUM TEXAPHYRIN; MACROCYCLIC COMPOUND;

ARTICLE; BIOAVAILABILITY; CANCER; CLINICAL TRIAL; COMPARTMENT MODEL; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HEALTH CARE PLANNING; HUMAN; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; TISSUE PERFUSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; METALLOPORPHYRINS; MICE; POPULATION; REPRODUCIBILITY OF RESULTS;

EID: 33646559565     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-5383-1     Document Type: Article

References (20)

1. Miller RA, Woodburn KW, Fan Q, Lee I, Miles D, Duran G, Sikic B, Magda D: Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res 7:3215-3221, 2001
2. Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA: In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol 45:981-989, 1999
3. Xu S, Zakian K, Thaler H, Matei C, Alfieri A, Chen Y, Koutcher JA: Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol 9:1381-1390, 2001
4. Young SW, Qing F, Harriman A, Sessler JL, Dow WC, Mody TD, Hemmi GW, Hao Y, Miller RA: Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. [published correction appears in Proc Natl Acad Sci USA. 96:2569, 1999]. Proc Natl Acad Sci USA 93:6610-6615, 1996
5. Mody TD, Fu L, Sessler JL: Texaphyrins: synthesis and development of a novel class of therapeutic agents, in: Karlin KD (ed): Progress in Inorganic Chemistry. New York, NY, John Wiley and Sons Inc, pp. 551-598, 2001
6. Evens AMI: Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer, Curr Opin Oncol 16:576-580, 2004
7. Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB, Miles D, Miller RA, Renschler MF: Multicenter Phase Ib/II Trial of the Radiation Enhancer Motexafin Gadolinium in Patients With Brain Metastases, J Clin Oncol 19(7):2074-2083, 2001
8. Mehta MP, Rodrigus P, Terhaard C, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz C, Timmerman R, Curran W, Smith J, Phan S, Miller R, Renschler M: Survival and Neurological Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases, J Clin Oncol 21(13):2529-2536, 2003
9. Meyers CA, Mehta MP, Rodrigus P, Dehnad H, Suh J, Roa W, Souhami L, Bezjak A, Komaki R, Schultz C, Timmerman R, Curran WJ, Phan S, Miller R, Renschler MF: Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial, J Clin Oncol 22:157-165, 2004
10. Jac J, Hernandez J, Phan S-C, Amato RJ: Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC). ASCO Abstract # 4724 J Clin Oncol 23(16S):433s, 2005
11. Miller RA, Woodburn K, Qing F, Renschler MF, Sessler JL, Koutcher JA: In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol 45(4):981-989, 1999
12. Ette EI, Kelman AW, Howie CA, Whiting B: Analysis of Animal Pharmacokinetic Data: performance of the One Point Per Animal Design. J Pharmacokinet and Biopharm 23(6):551-566, 1995
13. Boeckmann AJ, Sheiner LB, Beal SB: NONMEM User Guide Vols 1-5, San Francisco:NONMEM Project Group, 1994
14. Imbimbo BP, Martinelli P, Rocchetti M, Ferrari G, Bassotti G, Imbimbo E: Efficiency of different criteria for selecting pharmacokinetic multiexponential equations. Biopharm Drug Dispos 12:139-147, 1991
15. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV: Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 43(6):610-623, 2003
16. Parke J, Holford NHG, Charles BC: A procedure for generating bootstrap samples for the validation of nonlinear mixed-effect population models. Comput Meth Prog Bio 59:19-29, 1999
17. Sheiner LB, Beal SL: Same Suggestions for Measuring Predictive Performance. J Pharmacokin Biopharm 9(4):503-512, 1981
18. Davies B, Morris T: Physiological Parameters in Laboratory Animals and Humans. Pharm Res 10(7):1093-1095, 1993
19. Mani C, Upadhyay S, Lacy S, Boswell GW, Miles DR: Reductase-mediated metabolism of motexafin gadolinium (Xcytrin®) in rat and human liver subcellular fractions and purified enzyme preparations. J Pharm Sci 94(3):559-570, 2005
20. Miles DR, Smith JA, Phan S, Hutchinson SJ, Renschler MF, Ford JF, Boswell GW: Population Pharmacokinetics of Motexafin Gadolinium in Adults With Brain Metastases or Glioblastoma Multiforme. J of Clin Pharmacol 45(3):299-312, 2005